In a pooled analysis of databases of 6 different countries, the initiation of SGLT2i was associated with lower risks of CV outcomes, as compared with other glucose-lowering drugs.

CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.

Both baseline and lifetime alcohol intake were inversely associated with the risk of non-fatal CHD, and positively associated with the risk of ischemic and hemorrhagic stroke.

Patients with a transient ischemic attack or minor stroke had a sustained elevated risk of CV events up to 5 years after the first event, and approximately half of these events occurred after the first year.

Compared with placebo, alogliptin did not increase CV risk in type 2 diabetic patients up to 6 months after an ACS, or later.

Rivaroxaban therapy is not beneficial for the prevention of stroke recurrence and associated with a higher risk of bleeding compared to aspirin in patients with embolic stroke of undetermined source.

The European Commission (EC) has approved the use of evolocumab in patients with established atherosclerotic CVD (MI, stroke, PAD) to reduce CV risk.

Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.

Patients with hypertension with low platelet counts and high total homocysteine levels, which may promote platelet adherence, had the highest risk of first stroke, and this risk was reduced with folic acid treatment.

Individuals with at least one laboratory-confirmed respiratory infection had a higher risk of MI or stroke, in particular when infected with S. pneumoniae or influenza virus.

Different measures of fitness and physical activity were inversely associated with future CVD events and all-cause death, also in individuals with a high genetic CVD predisposition.

In a large prospective study, risk of all-cause mortality increases above 100 g alcohol per week, and positive associations with alcohol intake were seen mostly for stroke and HF, as opposed to MI.